References
1. Ørstavik R, Gustavson K, Rohrer-Baumgartner N, et al. ADHD i Norge: En statusrapport .https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2017/adhd_i_norge.pdf. Accessed June 1, 2022
2. Helsedirektoratet. ADHD: Nasjonal faglig retningslinje.https://www.helsedirektoratet.no/retningslinjer/adhd. Accessed June 1, 2022
3. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder.Lancet . Jul 16-22 2005;366(9481):237-48. doi:10.1016/S0140-6736(05)66915-2
4. Caye A, Rocha TB, Anselmi L, et al. Attention-Deficit/Hyperactivity Disorder Trajectories From Childhood to Young Adulthood: Evidence From a Birth Cohort Supporting a Late-Onset Syndrome. JAMA Psychiatry . Jul 1 2016;73(7):705-12. doi:10.1001/jamapsychiatry.2016.0383
5. Yu G, Li GF, Markowitz JS. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.J Child Adolesc Psychopharmacol . May 2016;26(4):314-26. doi:10.1089/cap.2015.0137
6. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology . Nov 2002;27(5):699-711. doi:10.1016/S0893-133X(02)00346-9
7. Hennissen L, Bakker MJ, Banaschewski T, et al. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine. CNS Drugs . Mar 2017;31(3):199-215. doi:10.1007/s40263-017-0410-7
8. Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet . 2005;44(6):571-90. doi:10.2165/00003088-200544060-00002
9. Trzepacz PT, Williams DW, Feldman PD, Wrishko RE, Witcher JW, Buitelaar JK. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol . Feb 2008;18(2):79-86. doi:10.1016/j.euroneuro.2007.06.002
10. Farid NA, Bergstrom RF, Ziege EA, Parli CJ, Lemberger L. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects.J Clin Pharmacol . May-Jun 1985;25(4):296-301. doi:10.1002/j.1552-4604.1985.tb02842.x
11. Witcher JW, Long A, Smith B, et al. Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder.J Child Adolesc Psychopharmacol . Spring 2003;13(1):53-63. doi:10.1089/104454603321666199
12. Brown JT, Bishop JR, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther . Jul 2019;106(1):94-102. doi:10.1002/cpt.1409
13. Choi CI, Bae JW, Lee YJ, Lee HI, Jang CG, Lee SY. Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. J Clin Psychopharmacol . Feb 2014;34(1):139-42. doi:10.1097/JCP.0b013e3182a608a2
14. Frost J, Bernard JP, Dietrichs ES, et al. Tidsskr Nor Laegeforen . Sep 24 2019;139(13)Nye anbefalinger ved serumkonsentrasjonsmalinger av sentralstimulerende legemidler. doi:10.4045/tidsskr.19.0385
15. Rudberg I, Mohebi B, Hermann M, Refsum H, Molden E. Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther . Feb 2008;83(2):322-7. doi:10.1038/sj.clpt.6100291
16. Waade RB, Hermann M, Moe HL, Molden E. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol . Aug 2014;70(8):933-40. doi:10.1007/s00228-014-1696-8
17. Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci . Jan 2020;13(1):116-124. doi:10.1111/cts.12692
18. Matsui A, Azuma J, Witcher JW, et al. Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men. J Clin Pharmacol . Mar 2012;52(3):388-403. doi:10.1177/0091270011398657
19. de Leon J. Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses? J Am Acad Child Adolesc Psychiatry . Jul 2015;54(7):532-4. doi:10.1016/j.jaac.2015.04.003
20. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry . Feb 2007;46(2):242-51. doi:10.1097/01.chi.0000246056.83791.b6
21. Fijal BA, Guo Y, Li SG, et al. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. J Clin Pharmacol . Oct 2015;55(10):1167-74. doi:10.1002/jcph.530
Tables
Table 1. Demographics of the study population.